Certara Inc. has recently released its 10-K report, providing an in-depth look at the company's financial performance and operations. The company, founded in 2008 and headquartered in Radnor, Pennsylvania, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. Its offerings include model-informed drug development, biosimulation solutions, software products for data automation, standardization, and validation, and regulatory submissions management software.
In the 2024 Annual Report on Form 10-K, Certara discusses the key factors affecting its performance, including customer retention and expansion, investments in growth, and the operating environment. The company highlights its focus on customer retention and expansion, with new bookings totaling $482.1 million in 2025, up from $445.3 million in 2024. Additionally, Certara's net retention rates have remained consistently high, averaging 105.3% for the full year in 2025.
The report also emphasizes Certara's investments in growth, including expanding the breadth and depth of its solutions through acquisitions and international expansion. The company expects its headcount to increase over time, leading to a rise in total operating expenses.
Furthermore, Certara addresses its operating environment, noting the impact of regulatory authorities' acceptance of model-informed biopharmaceutical discovery and development on the demand for its products and services. The company highlights the steady increase in the recognition of the role that modeling and simulation can play in the biopharmaceutical development and approval process, as demonstrated by new regulations and guidance documents.
The report also includes a discussion on non-GAAP measures, where Certara presents adjusted EBITDA, adjusted net income, and adjusted diluted earnings per share to aid investors in understanding its business. These measures are used by management to assess the performance of the business and evaluate the effectiveness of its strategies.
Certara's 10-K report provides a comprehensive overview of its financial condition, results of operations, and key factors affecting its performance, offering valuable insights into the company's position in the market and its strategic initiatives for future growth. As a result of these announcements, the company's shares have moved -0.1% on the market, and are now trading at a price of $9.51. For more information, read the company's full 10-K submission here.
